```
> E HANGELAND JON/AU 25
E1            1     HANGELAND ERIK/AU
E2            2     HANGELAND J J/AU
E3            2 --> HANGELAND JON/AU
E4            9     HANGELAND JON J/AU
E5            1     HANGELAND JON JOSEF/AU
E6            1     HANGELBROEK H H/AU
E7            2     HANGELBROEK R J/AU
E8            1     HANGEN DIETHER/AU
E9            3     HANGEN DONALD H/AU
E10           1     HANGEN E/AU
E11           4     HANGEN HERMANN OTTO/AU
E12           1     HANGEN L/AU
E13           1     HANGEN M/AU
E14           2     HANGEN MATTHIAS/AU
E15           1     HANGEN NINA/AU
E16           1     HANGEN THAD C/AU
E17           9     HANGEN U/AU
E18           2     HANGEN U D/AU
E19           6     HANGEN UDE/AU
E20           4     HANGEN UDE D/AU
E21           1     HANGENFELDT KERSTIN A/AU
E22           1     HANGER B/AU
E23          17     HANGER B C/AU
E24           1     HANGER C/AU
E25           3     HANGER CHRISTOPHER C/AU

=> S (E2 OR E3 OR E4 OR E5) AND (?THYROID?)
             2 "HANGELAND J J"/AU
             2 "HANGELAND JON"/AU
             9 "HANGELAND JON J"/AU
             1 "HANGELAND JON JOSEF"/AU
         96884 ?THYROID?
L1           1 ("HANGELAND J J"/AU OR "HANGELAND JON"/AU OR "HANGELAND JON J"/AU OR
"HANGELAND JON JOSEF"/AU) AND (?THYROID?)

=> DIS L1 1 IBIB ABS

L1   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2000:457018  CAPLUS
DOCUMENT NUMBER:          133:89793
TITLE:                    Preparation of 4-(4-hydroxyphenoxy)phenylacetyl amino
                          acids and related compounds as novel thyroid
                          receptor ligands
INVENTOR(S):              Hangeland, Jon; Zhang, Minsheng; Caringal,
                          Yolanda; Ryono, Denis; Li, Yi-lin; Malm, Johan; Liu,
                          Ye; Garg, Neeraj; Litten, Chris; Garcia Collazo, Ana
                          Maria; Koehler, Konrad
PATENT ASSIGNEE(S):       Karo Bio AB, Swed.; et al.
SOURCE:                   PCT Int. Appl., 60 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 2000039077      A2   20000706      WO 1999-IB2084   19991223
     WO 2000039077      A3   20000921
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
```

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2356319	AA	20000706	CA 1999-2356319	19991223	
BR 9916851	A	20011016	BR 1999-16851	19991223	
EP 1144370	A2	20011017	EP 1999-962486	19991223	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2002533432	T2	20021008	JP 2000-590990	19991223	
NO 2001002931	A	20010821	NO 2001-2931	20010613	

PRIORITY APPLN. INFO.: GB 1998-28442 A 19981224
WO 1999-IB2084 W 19991223

OTHER SOURCE(S): MARPAT 133:89793

GI



I

AB Title compds. I [R1 = halo, trifluoromethyl, alkyl, cycloalkyl; R2, R3 = H, halo, alkyl, at least one of R2 and R3 being other than H; n = 0-4; R4 is an (un)substituted heteroarom. moiety linked to (CH2)n via a nitrogen or carbon atom; an amine, including those in which the amine is derived from an alpha amino acid of either L- or D-stereochem., an acylsulfonamide, or a carboxylic acid amide, with the proviso that when n = 0, then R4 can only be a carboxylic acid amide or an acylsulfonamide; R5 is H or an acyl or other group capable of bioconversion to generate the free phenol structure] were prepd. for use in the treatment of diseases assocd. with metab. dysfunction or which are dependent on the expression of a T3 regulated gene (such as obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, **hypothyroidism**, goiter, **thyroid** cancer, glaucoma, cardiac arrhythmia, and congestive heart failure). Thus, coupling of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid with D-methionine Me ester hydrochloride followed by hydrolysis afforded N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]-D-methionine.